Modification of cellsensor irf1-bla TF-1 and irf1-bla HEL assays for direct comparison of wild-type JAK2 and JAK2 V617F inhibition

Assay and Drug Development Technologies

Volumn 9, Issue 3, 2011, Pages 311-318

  Mason, Jennifer L ^a   Holskin, Beverly P ^a   Murray, Kristen A ^a   Meyer, Sheryl L ^a   Wells Knecht, Kevin J ^a   Ator, Mark A ^a   Angeles, Thelma S ^a  

^a CEPHALON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE; INTERFERON REGULATORY FACTOR 1; JANUS KINASE 2;

ARTICLE; CELL ASSAY; CELL LINE; CELL LINE HEL; CELL LINE TF 1; ENZYME INHIBITION; HUMAN; HUMAN CELL;

BIOLOGICAL ASSAY; CELL LINE; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMANS; INTERFERON REGULATORY FACTOR-1; JANUS KINASE 2; PROTEIN ENGINEERING; PROTEIN KINASE INHIBITORS;

EID: 79957651219     PISSN: 1540658X     EISSN: 15578127     Source Type: Journal    
DOI: 10.1089/adt.2010.0297     Document Type: Article

References (22)

1. Baker SJ, Rane SG, Reddy EP: Hematopoietic cytokine receptor signaling. Oncogene 2007;26:6724-6737. (Pubitemid 47585098)
2. Luo C, Laaja P: Inhibitors of JAKs/STATs and the kinases: a possible new cluster of drugs. Drug Discov Today 2004;4:268-275. (Pubitemid 38328513)
3. Rane SG, Reddy E: JAKs, STATs and Src kinases in hematopoiesis. Oncogene 2002;21:3334-3358. (Pubitemid 34587707)
4. Li H, Zhang Y, Glass A, Zellweger T, Gehan E, Bubendorf L, et al.: Activation of signal transducer and activator of transcription 5 in human prostrate cancer is associated with high histological grade. Cancer Res 2004;64: 4774-4782. (Pubitemid 38924520)
5. Yu H, Jove R: The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 2004;4:97-105. (Pubitemid 38198738)
6. Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, et al.: Inhibiting STAT3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 2005;11:1314-1321. (Pubitemid 41752912)
7. Iwamaru A, Szymanski S, Iwado E, Aoki H, Yokoyama T, Fokt I, et al.: A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 2007;26:2435-2444. (Pubitemid 46597261)
8. Nefedova Y, Gabrilovich DI: Targeting of JAK/STAT pathway in antigen presenting cells in cancer. Curr Cancer Drug Targets 2007;7:71-77. (Pubitemid 46345509)
9. Ding B, Yu JJ, Yu RY, Mendez LM, Shaknovich R, Zhang Y, et al.: Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse B-cell lymphomas. Blood 2008;111: 1515-1523. (Pubitemid 351213441)
10. Benekli M, Baer MR, Baumann H, Wetzler M: Signal transducer and activator of transcription proteins in leukemias. Blood 2003;101:2940-2954. (Pubitemid 36857978)
11. Flex E, Petrangeli V, Stella L, Chiaretti S, Hornakova T, Knoops L, et al.: Somatically acquired JAK1 mutations in adult lymphoblastic leukemia. J ExpMed 2008;205:751-758. (Pubitemid 351549874)
12. Mercher T, Wernig G, Moore SA, Levine RL, Gu T-L, Frohling S, et al.: JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model. Blood 2006;108:2770-2779.
13. Walters DK, Mercher T, Gu T-L, OHare T, Tyner JW, Loriaux M, et al.: Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell 2006;10:65-75.
14. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al.: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-1061. (Pubitemid 40386783)
15. James C, Ugo V, Le CJP, Staerk J, Delhommeau F, Lacout C, et al.: A unique clonal JAK2 mutation leading of constitutive signaling causes polycythaemia vera. Nature 2005;434:1144-1148. (Pubitemid 40663494)
16. Kralovics R, Passamonti F, Buser AS, Buser AS, Teo SS, Tiedt R, et al.: A gain-offunction mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-1790. (Pubitemid 40570926)
17. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al.: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;387-397. (Pubitemid 40544655)
18. Robers MB, Machleidt T, Carlson CB, Bi K: Cellular LanthaScreen and blactamase reporter assays for high-throughput screening of JAK2 inhibitors. Assay Drug Dev Technol 2008;6:519-529.
19. Zhang J-H, Chung TDY, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4:67-73. (Pubitemid 29278954)
20. Thompson JE, Cubbon RM, Cummings RT, Wicker LS, Frankshun R, Cunningham BR, et al.: Photochemical preparation of a pyridine containing tetracycle: a JAK protein kinase inhibitor. Biorg Med Chem Lett 2002;12:1219-1223. (Pubitemid 34270567)
21. Baffert F, Regnier CH, De Pover, AD, Pissot-Soldermann, C, Tavares, GA, Blasco F, et al.: Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805. Mol Cancer Ther 2010;9: 1945-1955.
22. Binder C, Lafayette A, Archibeque I, Sun Y, Plewa C, Sinclair A, et al.: Optimization and utilization of the SureFire Phospho-STAT5 assay for a cellbased screening campaign. Assay Drug Dev Technol 2008;6:27-37. (Pubitemid 351380169)